Business
Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting
Accuray Incorporated (NASDAQ: ARAY) announced today that new data on the clinical use of the CyberKnife® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors. Malignant brain and other CNS tumors are considered to be some of the most fatal types of cancer and contribute to significant morbidity and mortality in the United States 1. The studies, involving the delivery of stereotactic radiosurgery (SRS) and stereotactic body radiation t
About this update from Accuray Incorporated
[{"type":"text","content":"Data Also Highlights Continued Clinical Advances Using the CyberKnife System That are Making High Quality Care an Option for People Who Previously Had Limited Choices","length":167,"tagName":"p","attribs":{}},{"type":"text","content":"MADISON, Wis., April 3, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data on the clinical use of the CyberKnife® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors. Malignant brain and other CNS tumors are considered to be some of the most fatal types of cancer and contribute to significant morbidity and mortality in the United States 1. The studies, involving the delivery of stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), were presented at the recent 2025 Radiosurgery Society (RSS) Scientific Meeting in Tucson, Arizona.","length":668,"tagName":"p"},{"type":"image","alt":"Accuray CyberKnife(R) System","displaySize":"","headline":null,"caption":"Accuray CyberKnife(R) System","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":310,"url":"https://media.zenfs.com/en/prnewswire.com/05bfb70763b1a65d0c7b95a9dcff1078"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tsW.mVRp8JZaDbJnxQ7Rmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTU0NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/05bfb70763b1a65d0c7b95a9dcff1078","width":400,"height":310}},"href":"https://mma.prnewswire.com/media/2657076/Accuray_CyberKnife__R__System.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"SRS and SBRT are non-surgical procedures that deliver precisely targeted doses of radiotherapy, typically in one to five treatment sessions, with the goal of ablating (destroying) the tumor or lesion. To achieve the accuracy and precision required, the CyberKnife System uses image guidance during treatment, and leverages potentially 1,000 different beam angles targeting the tumor as well as Synchrony® adaptive delivery, which adjusts the aim of the beam in real time to correct for tumor or patient motion.","length":510,"tagName":"p"},{"type":"text","content":""The studies presented at this year's Radiosurgery Society meeting underscore both the long-term efficacy and expanding applications of the CyberKnife System. Whether treating benign tu...